深圳市美好创亿医疗科技股份有限公司 2025 年第三季度报告 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 重要内容提示： 证券代码：301363 证券简称：美好医疗 公告编号：2025-068 深圳市美好创亿医疗科技股份有限公司 1.董事会及董事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担 个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、准确、 完整。 3.第三季度财务会计报告是否经过审计 □是 否 1 深圳市美好创亿医疗科技股份有限公司 2025 年第三季度报告 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 461,657,375.39 ...

美好医疗公告，公司2025年前三季度实现归属于上市公司股东净利润2.08亿元。公司拟以总股本5.68亿 股为基数，向全体股东按每10股派发现金红利0.80元（含税），合计派发现金红利4541.91万元（含 税）。本次不送红股，不进行资本公积转增股本。 ...

美好医疗公告，第三季度营收为4.62亿元，同比增长2.56%；净利润为9390.02万元，同比增长5.89%。 前三季度营收为11.94亿元，同比增长3.28%；净利润为2.08亿元，同比下降19.25%。 ...

Core Insights - The medical device CDMO sector in China is experiencing growth driven by policy support and increasing demand, with expectations to replicate the successful trajectory of the pharmaceutical CXO model over the next five years [1][6]. Policy Support - The China Federation of Logistics and Purchasing reported that the market size of the medical device industry is projected to reach 1.2 trillion yuan by 2024 [1]. - The implementation of the MAH system allows R&D companies to outsource production, providing significant policy support for the industry [2]. - The demand for innovation and cost control due to centralized procurement and medical insurance payment reforms is pushing companies to focus on medical device CDMO [2]. Industry Landscape - The global medical device CDMO market is expected to grow at a compound annual growth rate (CAGR) of 16.3% from 2020 to 2025, significantly outpacing the overall medical device industry growth [2]. - Domestic companies are rapidly entering the CDMO space, with firms like Meihao Medical providing comprehensive services from product development to mass delivery [3]. - High-end medical device sectors, such as surgical robots, show a particularly strong demand for CDMO platforms, which can facilitate faster product development and compliance [4]. Company Strategies - Companies are increasingly collaborating with CDMO platforms to enhance their product development capabilities and reduce time to market [4]. - Non-medical device companies, such as Huoyi Technology, are also entering the CDMO space, leveraging technology transfer and attracting global talent [4]. - The industry is characterized by a fragmented "specialized and precise" model, with a focus on specialized processes and engineering experience [5]. Future Outlook - The medical device CDMO sector is at a critical transition phase, moving from niche markets to broader product lines and upgrading from traditional OEM to full-service CDMO offerings [6]. - Key growth areas include high-value consumables, precision processing, and automated sterilization platforms [6]. - The industry is expected to face challenges such as talent shortages and insufficient intellectual property protection, necessitating coordinated efforts for talent development and regulatory compliance [7]. Development Pathways - The industry is likely to see the emergence of 1-2 leading companies capable of providing integrated services from R&D to mass production within the next 3-5 years [8]. - Companies are encouraged to focus on single market segments initially, ensuring quality and delivery efficiency before expanding into adjacent categories through mergers and acquisitions [8].

Core Insights - The medical device CDMO sector in China is experiencing significant growth driven by policy support and surging demand, with expectations to replicate the successful trajectory of the pharmaceutical CXO model over the next five years [1][7]. Policy Support - The Chinese medical device market is projected to reach 1.2 trillion yuan by 2024, indicating robust growth potential [2]. - Global leaders in the medical device industry have long outsourced production to specialized CDMO providers to enhance R&D efficiency and reduce time-to-market for new products [2]. - The implementation of the MAH system allows R&D companies to outsource production, providing a significant policy boost to the industry [3]. Industry Demand - There is a growing demand for CDMO services in high-end medical equipment sectors, particularly in surgical robotics, where innovative companies require robust support for product commercialization [5]. - The medical device CDMO market is expected to grow rapidly, with a projected annual compound growth rate of 16.3% from 2020 to 2025, significantly outpacing the overall medical device industry growth [2]. Company Developments - Companies like Meihua Medical are actively expanding their CDMO capabilities, offering comprehensive services from product development to mass delivery across various medical device segments [4]. - The establishment of high-end medical device CDMO platforms, such as Shuimu Dongfang, is facilitating the acceleration of product development and market entry for innovative projects [5]. Market Trends - The Chinese medical device CDMO sector is transitioning from a focus on specific segments like IVD to a broader range of product lines and full-service capabilities [7]. - The industry is characterized by a fragmented landscape with a focus on specialized, high-quality services rather than large-scale operations [6]. Future Outlook - The next 3-5 years are critical for the industry, with expectations for the emergence of 1-2 leading companies capable of providing integrated services from R&D to mass production [9]. - Key growth areas include high-value consumables, automated filling and sterilization platforms, and the development of accelerators for prototype registration and small batch production [7].

Core Viewpoint - The stock of Meihao Medical (301363) has shown a slight decline, with recent trading data indicating mixed capital flows and performance metrics compared to industry averages [1][2][3]. Group 1: Stock Performance - As of October 16, 2025, Meihao Medical's stock closed at 23.13 yuan, down 0.04%, with a trading volume of 57,800 hands and a total transaction amount of 134 million yuan [1]. - The net inflow of main funds on October 16 was 13.05 million yuan, accounting for 9.72% of the total transaction amount, while retail investors experienced a net outflow of 10.73 million yuan, representing 8.00% of the total [1][2]. Group 2: Financial Metrics - Meihao Medical's total market value is 13.158 billion yuan, with a net asset of 3.595 billion yuan and a net profit of 114 million yuan [3]. - The company's revenue for the first half of 2025 was 733 million yuan, a year-on-year increase of 3.73%, while the net profit decreased by 32.44% to 114 million yuan [3]. - The gross profit margin stands at 37.52%, which is significantly lower than the industry average of 51.85% [3]. Group 3: Industry Comparison - In terms of valuation, Meihao Medical has a price-to-earnings ratio of 57.56, which is lower than the industry average of 66.63, and a price-to-book ratio of 3.66, compared to the industry average of 3.81 [3]. - The company ranks 25th in total market value and 42nd in net assets within the medical device industry [3]. Group 4: Analyst Ratings - Over the past 90 days, 17 institutions have rated Meihao Medical, with 15 buy ratings and 2 hold ratings, indicating a generally positive outlook [4]. - The average target price set by institutions for the stock is 24.42 yuan [4].

Core Viewpoint - The Chinese innovative pharmaceutical sector is experiencing significant growth, with companies transitioning from generic to innovative drug development, and is expected to continue as a key investment theme in the medium to long term [1][2]. Group 1: Market Performance - The three major A-share indices rose collectively in early trading, with the Shanghai Composite Index up 0.1% to 3916.1 points, the Shenzhen Component Index up 0.15%, and the ChiNext Index up 0.69% [1]. - The total trading volume in the Shanghai and Shenzhen markets reached 12,229 billion yuan, a decrease of 576 billion yuan from the previous day, with over 1,200 stocks rising [1]. Group 2: Innovative Drug Sector - The innovative drug concept stocks strengthened again, with various Hong Kong innovative drug ETFs rising over 2% [1]. - The upcoming European Society for Medical Oncology (ESMO) conference in October 2025 is anticipated to showcase new data from innovative drug companies, including domestic firms like Kangfang Biotech and Hengrui Medicine [1]. Group 3: Industry Insights - The Chinese pharmaceutical industry has completed a transition from old to new growth drivers, with innovative drugs significantly opening new growth avenues for companies [1]. - Major traditional pharmaceutical companies like Hengrui Medicine and Hansoh Pharmaceutical have successfully transformed into innovative firms, while emerging companies are rapidly gaining global recognition [1]. - The aging population is driving demand for chronic disease treatments, contributing to the growth of the silver economy [1]. - The healthcare payment system is steadily growing, with the National Healthcare Security Administration promoting the development of commercial insurance [1]. - The rise of AI is expected to introduce new growth logic in the pharmaceutical industry, with a positive outlook for innovative drugs and medical devices [1]. Group 4: Investment Recommendations - The innovative drug sector is projected to maintain high revenue growth and reduce losses, with Q3 expected to continue this trend [2]. - Investment opportunities are suggested in sectors with improving performance, such as CXO, upstream scientific reagents, and medical devices [2].

10月16日重点关注的财经要闻与资本市场大事： 10月16日至18日，2025世界智能网联汽车大会将举行，大会将围绕智能网联汽车产业的政策、技术、安 全、人工智能、应用、数据等方向进行深度探讨。 3、3220.1亿元市值限售股今日解禁 10月16日，共有13家公司限售股解禁，合计解禁量为9.38亿股，按最新收盘价计算，合计解禁市值为 220.1亿元。 从解禁量来看，6家公司解禁股数超千万股。美好医疗、上大股份、中钨高新解禁量居前，解禁股数分 别为2.17亿股、2.07亿股、1.89亿股。从解禁市值来看，6家公司解禁股数超亿元。上大股份、美好医 疗、铭利达解禁市值居前，解禁市值分别为67.81亿元、50.21亿元、38.82亿元。 1、商务部将召开新闻发布会 介绍近期商务领域重点工作有关情况 10月16日下午3时，商务部将举行新闻发布会，新闻发言人介绍近期商务领域重点工作有关情况，并答 记者问。 2、2025世界智能网联汽车大会将举行 （原标题：今日看点｜商务部将召开新闻发布会，介绍近期商务领域重点工作有关情况） 4、17家公司披露回购进展 10月16日，17家公司共发布17个股票回购相关进展。其中，3家公司首 ...

Group 1 - On October 16, a total of 13 companies had their restricted shares unlocked, with a total unlock volume of 938 million shares [1] - The total market value of the unlocked shares is approximately 22.01 billion yuan based on the latest closing prices [1] - The companies with the highest unlock volumes are Meihao Medical, Shangda Shares, and Zhongtung High-tech, with unlock volumes of 217 million shares, 207 million shares, and 189 million shares respectively [1] Group 2 - In terms of unlock market value, Shangda Shares, Meihao Medical, and Minglida lead with market values of 6.781 billion yuan, 5.021 billion yuan, and 3.882 billion yuan respectively [1] - The companies with the highest proportion of unlocked shares relative to total share capital are Guanlong Energy Saving, Shangda Shares, and Minglida, with unlock ratios of 66.93%, 55.68%, and 42.12% respectively [1]

证券之星消息，截至2025年10月15日收盘，美好医疗(301363)报收于23.14元，上涨2.71%，换手率 3.48%，成交量5.44万手，成交额1.25亿元。 10月15日的资金流向数据方面，主力资金净流入195.35万元，占总成交额1.57%，游资资金净流出 630.18万元，占总成交额5.06%，散户资金净流入434.83万元，占总成交额3.49%。 近5日资金流向一览见下表： 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 游资净占比 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-15 | 23.14 2.71% | 195.35万 | 1.57% | -630.18万 | -5.06% | 434.83万 | 3.49% | | 2025-10-14 | 22.53 -3.22 ...